Arvinas is a clinical-stage biopharmaceutical company (NASDAQ: ARVN) headquartered in New Haven, Connecticut, developing targeted protein degradation therapeutics using its proprietary PROTAC (proteolysis targeting chimera) Discovery Engine. - View it on GitHub